Lanxess' Saltigo business unit saw "robust" performance in Q1. The unit was less affected by declining demand from customer industries than in Lanxess' other business units. However Saltigo did see some decline in its pharmaceutical intermediates business due to product launch delays.
Lanxess
Sunday 10 May 2009
Pharma declines for Saltigo
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment